Alkermes climbs as Evercore upgrades stock to 'outperform'

Alkermes

24/10/2023 16:37

** Shares of drugmaker Alkermes  ALKS.O  rise ~2.8% to
$25.12
    ** Evercore upgrades ALKS stock rating to "outperform" from
"in line"
    ** The early-stage study for ALKS' narcolepsy drug shows
that it is clearly very active and potent - brokerage
    ** Narcolepsy is a chronic neurological disorder that
affects brain's ability to control sleep-wake cycles.
    ** Six of 11 brokerages rate stock "buy" or higher, 5
"hold"; median PT is $35 - LSEG data
    ** Including session's move, stock down ~3.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))